Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $54.0 million.

  • Stoke Therapeutics' Shares Outstanding (Diluted Average) rose 7.20% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 7.20%. This contributed to the annual value of $54.0 million for FY2024, which is 22.76% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Shares Outstanding (Diluted Average) of $54.0 million as of FY2024, which was up 22.76% from $44.0 million recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Shares Outstanding (Diluted Average) peaked at $54.0 million during FY2024, and registered a low of $38.9 million during FY2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $45.6 million, with a median of $44.0 million in 2023.
  • Data for Stoke Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 22.76% (in 2024) over the last 5 years.
  • Stoke Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $38.9 million in 2022, then climbed by 13.10% to $44.0 million in 2023, then increased by 22.76% to $54.0 million in 2024.